Spots Global Cancer Trial Database for Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Official Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination With Cetuximab in Patients With Advanced Biliary Cancer.

Study ID: NCT00552149

Conditions

Advanced Biliary Cancer

Interventions

Gemox, Cetuximab

Study Description

Brief Summary: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.

Detailed Description: The BINGO trial is an open-label randomized phase II study evaluating the efficacy and tolerance of gemcitabine-oxaliplatin combination chemotherapy (GEMOX regimen) alone or in combination with cetuximab in patients (pts) with ABC. The BINGO study also comprises ancillary translational research and functional imaging studies which aim to identify markers predictive for treatment efficacy in ABC. All eligible pts will be randomized 1:1 to receive: * Arm A: GEMOX alone every two weeks. * Arm B: GEMOX + cetuximab every two weeks. Randomization will be stratified according to: 1. tumor stage (locally advanced vs metastatic), 2. primary tumor location (gallbladder vs non-gallbladder), 3. prior treatments (surgery or radiotherapy or brachytherapy or photodynamic therapy \[PDT\] or adjuvant chemotherapy vs none), 4. center. EGFR tumor status has to be assessed for every pt by immunohistochemistry (IHC) using biopsy or surgical material, at any time prior to inclusion into the study, but it is neither an inclusion/exclusion criterion nor a stratification factor.